In a nutshell This phase 3 trial aims to evaluate how well aspirin can work to prevent recurrence of breast cancer. The main outcome to be investigated is invasive disease free survival. Other outcomes include overall survival (time from treatment until death from any cause) and the incidence of heart disease. This trial is taking place in 985...
Read MoreCurrent treatment status-Not currently treated Posts on Medivizor
What are the cardiovascular risks of surgical castration compared to hormone therapy?
In a nutshell This study aimed to compare the risk of cardiovascular incidents (CIs, side-effects) of surgical castration versus castration achieved by hormone therapy. The study concluded that CIs were higher for surgical treatment at 1.5 years after treatment, but similar thereafter. Some background For locally advanced or metastatic...
Read MoreRisk of central nervous system tumors in long-term survivors of childhood ALL or AML
In a nutshell This study examined the risk of developing central nervous system (CNS) tumors in childhood leukemia patients who underwent allogeneic (from a matched donor) stem cell transplantation. This study concluded that childhood leukemia patients have an increased risk of later developing CNS tumors. Some background Improvements in...
Read MoreLooking for patients to test the safety of engineered T-cells with durvalumab in treating diffuse large B-cell lymphoma
In a nutshell This phase 1 clinical trial will test the safety of a JCAR014 engineered T cells and durvalumab (MEDI4736) combination in treating recurrent or refractory (unresponsive to treatment) non-Hodgkin’s lymphoma. The primary outcome will be measured by evaluating the movement of the engineered T cells throughout the body and side...
Read MoreLooking for patients with chronic myelogenous leukemia or Philadelphia chromosome positive acute lympholastic leukemia to test a BCR-ABL1 inhibitor
In a nutshell This phase 1 clinical trial will test the safety of ABL001 alone and with either nilotinib (Tasigna), imatinib (Gleevec), or dasatinib (Sprycel) in patients with chronic myelogenous leukemia (CML) or Philadelphia chromosome-positive acute lymphoblastic Leukemia (Ph+ALL). The primary outcome will be measured by side effects. The details...
Read MoreThe benefit of exercise before and after prostate cancer diagnosis
In a nutshell The authors aimed to determine the benefit of exercise before and after prostate cancer diagnosis and its effect on prostate cancer-specific mortality in men. The authors concluded that men with non-metastatic (cancer that has not spread into surrounding organs) prostate cancer who exercised more after diagnosis had a lower risk of...
Read MoreThe use of platelet to lymphocyte ratio in predicting prostate cancer outcome
In a nutshell The authors aimed to determine the predicting value of the platelet to lymphocyte ratio (PLR) in prostate cancer patients treated with hormone therapy. The authors concluded that the PLR might play a significant role in the prognosis of prostate cancer patients treated with hormone therapy. Some background The PLR is based on the...
Read MoreIs targeted chemotherapy for stage II/III rectal cancer before surgery effective?
In a nutshell This study examined the effect of pre-surgical chemotherapy without radiotherapy in stage II/III rectal cancer. The study showed that combined targeted chemotherapy was effective in these patients. Some background Rectal cancer is a cancer of the end part of the digestive system. In stage II and III, the cancer has begun to...
Read MoreOccurrence of new cancers after rituximab treatment for patients with diffuse large B-cell lymphoma
In a nutshell The authors examined whether rituximab was associated with the development of a second cancer after treatment for diffuse large B-cell lymphoma. The authors concluded that the number of patients with certain cancers has increased after rituximab was introduced. Some background Diffuse large B-cell lymphoma (DLBCL) is a very...
Read MoreLooking at immunotherapy for late stage non-small-cell lung cancer
In a nutshell This trial looked at the effectiveness of the immunotherapy nivolumab (Opdivo) for patients with advanced non-small-cell lung cancer (NSCLC). The authors concluded that nivolumab resulted in similar survival rates compared to chemotherapy. They did however state that it was safer in terms of side effects. Some background Chemotherapy...
Read MoreSearching for advanced non-small cell lung cancer patients to treat a combination of immunotherapy and radiation
In a nutshell This phase 2 clinical trial will test the effectiveness of FLT3 ligand immunotherapy in combination with stereotactic body radiotherapy (SBRT) in advanced non-small cell lung cancer (NSCLC). The main outcome of this trial will be measured as the time to disease progression. This study is being conducted in New York City. The details...
Read MoreLooking for patients with a KRAS or EGFR mutation to test a combination of MEK162 with erlotinib
In a nutshell This phase I/IB trial aims to determine whether combining MEK162(ARRY-162) and erlotinib (Tarceva) is safe and effective at treating patients with stage IV non-small cell lung cancer (NSCLC) with KRAS or EGFR mutations and no curative treatment options. The main outcome of the trial will be maximum tolerated dose (MTD – highest dose...
Read More
